134 related articles for article (PubMed ID: 33290794)
41. Activatable Polymeric Nanoprobe for Near-Infrared Fluorescence and Photoacoustic Imaging of T Lymphocytes.
Zhang Y; He S; Chen W; Liu Y; Zhang X; Miao Q; Pu K
Angew Chem Int Ed Engl; 2021 Mar; 60(11):5921-5927. PubMed ID: 33305425
[TBL] [Abstract][Full Text] [Related]
42. Click Chemistry in the Design and Production of Hybrid Tracers.
Hensbergen AW; van Willigen DM; Welling MM; van der Wijk FA; de Korne CM; van Oosterom MN; Schottelius M; Wester HJ; Buckle T; van Leeuwen FWB
ACS Omega; 2019 Jul; 4(7):12438-12448. PubMed ID: 31460363
[TBL] [Abstract][Full Text] [Related]
43. Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma.
Gunassekaran GR; Hong CM; Vadevoo SMP; Chi L; Guruprasath P; Ahn BC; Kim HJ; Kang TH; Lee B
Biomaterials; 2018 Mar; 159():161-173. PubMed ID: 29329051
[TBL] [Abstract][Full Text] [Related]
44. Molecular imaging in tracking tumor-specific cytotoxic T lymphocytes (CTLs).
Liu Z; Li Z
Theranostics; 2014; 4(10):990-1001. PubMed ID: 25157278
[TBL] [Abstract][Full Text] [Related]
45. Targeting lymphotoxin beta receptor with tumor-specific T lymphocytes for tumor regression.
Yang D; Ud Din N; Browning DD; Abrams SI; Liu K
Clin Cancer Res; 2007 Sep; 13(17):5202-10. PubMed ID: 17785576
[TBL] [Abstract][Full Text] [Related]
46. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.
Chapuis AG; Roberts IM; Thompson JA; Margolin KA; Bhatia S; Lee SM; Sloan HL; Lai IP; Farrar EA; Wagener F; Shibuya KC; Cao J; Wolchok JD; Greenberg PD; Yee C
J Clin Oncol; 2016 Nov; 34(31):3787-3795. PubMed ID: 27269940
[TBL] [Abstract][Full Text] [Related]
47. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes.
Fenton RG; Taub DD; Kwak LW; Smith MR; Longo DL
J Natl Cancer Inst; 1993 Aug; 85(16):1294-302. PubMed ID: 8340941
[TBL] [Abstract][Full Text] [Related]
48. A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults.
LaVoy EC; Bollard CM; Hanley PJ; Blaney JW; O'Connor DP; Bosch JA; Simpson RJ
Exerc Immunol Rev; 2015; 21():144-53. PubMed ID: 25826370
[TBL] [Abstract][Full Text] [Related]
49. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
50. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
51. Differential biodistribution of intravenously administered endothelial progenitor and cytotoxic T-cells in rat bearing orthotopic human glioma.
Varma NR; Shankar A; Iskander A; Janic B; Borin TF; Ali MM; Arbab AS
BMC Med Imaging; 2013 Jun; 13():17. PubMed ID: 23758888
[TBL] [Abstract][Full Text] [Related]
52. Trafficking of tumor peptide-specific cytotoxic T lymphocytes into the tumor microcirculation.
Ali S; Ahmad M; Lynam J; Rees RC; Brown N
Int J Cancer; 2004 Jun; 110(2):239-44. PubMed ID: 15069688
[TBL] [Abstract][Full Text] [Related]
53. Fluorescence background quenching as a means to increase Signal to Background ratio - a proof of concept during Nerve Imaging.
Buckle T; van der Wal S; van Willigen DM; Aalderink G; KleinJan GH; van Leeuwen FWB
Theranostics; 2020; 10(21):9890-9898. PubMed ID: 32863966
[No Abstract] [Full Text] [Related]
54. Cytotoxic T lymphocytes generated by short-term in vitro TCR stimulation in the presence of IL-4 are therapeutically effective against B16 melanoma.
Chang ML; Chen YT; Su YC; Kung JT
J Biomed Sci; 2003; 10(6 Pt 1):644-50. PubMed ID: 14576467
[TBL] [Abstract][Full Text] [Related]
55. Novel Liposomal Azido Mannosamine Lipids on Metabolic Cell Labeling and Imaging via Cu-Free Click Chemistry.
Shen L; Cai K; Yu J; Cheng J
Bioconjug Chem; 2019 Sep; 30(9):2317-2322. PubMed ID: 31403278
[TBL] [Abstract][Full Text] [Related]
56. In-Vivo Detection and Tracking of T Cells in Various Organs in a Melanoma Tumor Model by 19F-Fluorine MRS/MRI.
Gonzales C; Yoshihara HA; Dilek N; Leignadier J; Irving M; Mieville P; Helm L; Michielin O; Schwitter J
PLoS One; 2016; 11(10):e0164557. PubMed ID: 27736925
[TBL] [Abstract][Full Text] [Related]
57. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
[TBL] [Abstract][Full Text] [Related]
58. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors.
Huang H; Liu Y; Xiang J
Cell Immunol; 2002; 217(1-2):12-22. PubMed ID: 12425997
[TBL] [Abstract][Full Text] [Related]
59. Suppression of an already established tumor growing through activated mucosal CTLs induced by oral administration of tumor antigen with cholera toxin.
Wakabayashi A; Nakagawa Y; Shimizu M; Moriya K; Nishiyama Y; Takahashi H
J Immunol; 2008 Mar; 180(6):4000-10. PubMed ID: 18322209
[TBL] [Abstract][Full Text] [Related]
60. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
Stastny MJ; Brown CE; Ruel C; Jensen MC
J Pediatr Hematol Oncol; 2007 Oct; 29(10):669-77. PubMed ID: 17921847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
